Soluble CD95 Ligand Role in the Pathophysiology of Antineutrophil

Status Recruiting

Clinical Trial Summary

The study aims at defining the role of soluble CD95 Ligand in the physiopathology of a rare group of inflammatory diseases: ANCA associated vasculitis. Soluble CD95 Ligand might have a prognostic and diagnostic interest as well as potential for the discovery of new therapeutic strategies.

Clinical Trial Description

ANCA associated vasculitis are a rare group of diseases and potentially life-threatening inflammatory conditions. There is an urgent need to describe prognostic factors and to discover new therapeutic pathways. Soluble CD95-L is a cleaved part of CD95-L which binds the CD95 Death receptor. s-CD95-L has pro-inflammatory properties for Th17 lymphocytes and Neutrophils, two cells implicated in ANCA associated vasculitis. It also plays a role in systemic lupus erythematosus (which present with the same type of renal glomerulonephritis as ANCA-associated vasculitis). Finally, it has already be found elevated in this group of diseases. The investigators hypothesized that s-CD95-L levels might be a prognostic factor in ANCA associated vasculitis and the study of the molecular mechanisms involved could provide new therapeutic targets. The study will recruit 50 patients with ANCA associated vasculitis followed in Bordeaux University Hospital. Among classical disease activity information, blood and urine samples will be collected at each visit to study s-CD95-L. Fundamental research will be realized on patients' sample to study molecular mechanisms involved. Clinical and biological disease activity, treatment and outcomes will be studied in correlation with s-CD95-L to describe their potential prognostic role. Patients will be followed at regular intervals, as their usual follow-up would request. No extra visit will be needed and blood samples will be drawn at the same time as those drawn for clinical purposes. ;

Study Design

Related Conditions & MeSH terms

ANCA Associated Vasculitis
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Vasculitis

Clinical Trial Details

NCT number	NCT03698071
Study type	Interventional
Source	University Hospital, Bordeaux
Contact	Patrick BLANCO, Prof
Phone	(0)5 56 79 56 45
Email	patrick.blanco@chu-bordeaux.fr
Status	Recruiting
Phase	N/A
Start date	December 14, 2018
Completion date	December 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03942887` - Exploring Durable Remission With Rituximab in Antineutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis	Phase 3
Completed	`NCT04895878` - Patients With Co-occurrence of ANCA Vasculitis and Sjögren Syndrome
Completed	`NCT00293072` - Pilot Study of Rituximab Therapy for Systemic Lupus Erythematosus (SLE) and Vasculitis	Phase 2
Recruiting	`NCT04664465` - PRediction Of DIverse Glucocorticoids toxIcity OUtcomeS
Recruiting	`NCT05315141` - Multicenter Cohort Study of AAV in Hunan of China
Recruiting	`NCT05376319` - PR3-AAV Resilient Remission or PRRR	Phase 2
Recruiting	`NCT04737343` - Comparison of the Efficacy of Leflunomide and Azathioprine for the Maintenance Therapy of ANCA Associated Vasculitis	N/A
Recruiting	`NCT05962840` - Efficacy and Safety for Rituximab Combined With Telitacicept in the Treatment of ANCA-associated Vasculitis (TTCAAVREM)	Phase 4
Suspended	`NCT03906227` - Tailoring Maintenance Therapy to Cluster of Differentiation 5 Positive (CD5+) Regulatory B Cell Recovery in ANCA Vasculitis	N/A
Not yet recruiting	`NCT06152172` - CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101	Phase 1
Not yet recruiting	`NCT05946564` - A Trial to Evaluate the Efficacy of Pioglitazone to Promote Renal Tolerance in ANCA-associated Vasculitis - RENATO Trial	Phase 3
Recruiting	`NCT04923074` - the Application of Diffusion Tensor Imaging in the Evaluation of Peripheral Neuropathy in ANCA Associated Vasculitis
Active, not recruiting	`NCT01633476` - CMV Modulation of the Immune System in ANCA-associated Vasculitis	Phase 2
Not yet recruiting	`NCT05416723` - Occupational and Environmental Origins of ANCA Vasculitis: Contribution of Data From the National Network for Vigilance and Prevention of Occupational Pathologies (RNV3P)
Recruiting	`NCT06277427` - Refractory ANCA Associated Vasculitis and Lupus Nephritis Treated With BCMA-targeting CAR-T Cells	N/A
Active, not recruiting	`NCT03967925` - Rituximab and Belimumab Combination Therapy in PR3 Vasculitis	Phase 2
Recruiting	`NCT05630612` - ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC)	Phase 2
Recruiting	`NCT04316494` - Hydroxychloroquine in ANCA Vasculitis Evaluation	Phase 4
Completed	`NCT04973033` - Effect of Tofacitinib in Treating ANCA-associated Vasculitis	N/A
Recruiting	`NCT06373081` - Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Soluble CD95 Ligand Role in the Pathophysiology of Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis — VASC-FAS

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms